CSTL CASTLE BIOSCIENCES INC

Nasdaq castlebiosciences.com


$ 31.14 $ 4.71 (17.49 %)    

Tuesday, 04-Nov-2025 19:45:50 EST
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 31.63
$ 26.93
$ 25.63 x 100
$ 33.00 x 40
$ 26.01 - $ 31.84
$ 14.59 - $ 35.84
1,514,092
na
923.24M
$ 1.63
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-30-2025 10-Q
2 08-04-2025 06-30-2025 10-Q
3 05-05-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-05-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-02-2023 06-30-2023 10-Q
11 05-03-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-02-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-08-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-11-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-10-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 09-03-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-maintains-outperform-on-castle-biosciences-raises-price-target-to-41

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from...

 castle-biosciences-rolls-out-advancead-tx-gene-expression-profile-test-to-guide-treatment-for-moderate-to-severe-atopic-dermatitis

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ann...

 castle-biosciences-raises-fy2025-sales-guidance-from-310000m-320000m-to-327000m-335000m-vs-317599m-est

Castle Biosciences (NASDAQ:CSTL) raises FY2025 sales outlook from $310.000 million-$320.000 million to $327.000 million-$335.00...

 castle-biosciences-q3-adj-eps-002-beats-052-estimate-sales-83043m-beat-71209m-estimate

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(...

 decisiondx-melanoma-validated-across-cutaneous-melanoma-subtypes-in-13560-patients-with-results-to-be-presented-by-castle-biosciences-at-dermatology-conference

This new histological subtype data confirms DecisionDx-Melanoma's clinical value across the spectrum of melanomaCastle Bios...

 castle-biosciences-study-finds-15-of-barretts-esophagus-patients-face-higher-cancer-risk-than-pathology-suggests

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-expands-decisiondx-scc-test-to-predict-local-recurrence-in-high-risk-skin-cancer-patients

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-raises-fy2025-sales-guidance-from-28700m-29700m-to-31000m-32000m-vs-29410m-est

Castle Biosciences (NASDAQ:CSTL) raises FY2025 sales outlook from $287.00 million-$297.00 million to $310.00 million-$320.00 mi...

 castle-biosciences-q2-adj-eps-015-beats-049-estimate-sales-8619m-beat-7153m-estimate

Castle Biosciences (NASDAQ:CSTL) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $(...

 castle-biosciences-decisiondx-melanoma-test-granted-breakthrough-device-designation-by-fda

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-signs-collaboration-and-license-agreement-with-scibase-to-develop-atopic-dermatitis-flare-prediction-test-using-electrical-impedance-spectroscopy-technology

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-announces-it-will-present-research-aimed-at-enhancing-the-clinical-management-of-patients-with-cutaneous-melanoma-and-uveal-melanoma-at-the-2025-american-society-of-clinical-oncology-annual-meeting

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will prese...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION